This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2026 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.80% per year. These returns cover a period from January 1, 1988 through August 3, 2026. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Zacks Initiates Coverage of Iridex With Neutral Recommendation
by Debasmita Chatterjee
Discover why Zacks initiated coverage of IRIX with a "Neutral" rating, being the first on Wall Street to initiate coverage on the stock. Learn how global sales momentum and stronger liquidity are balanced against margin pressures and dependency on a key distributor.
RMTI Stock Rises 138% in Q3: What Should You Do Ahead of Earnings?
by Urmimala Biswas
Rockwell Medical expects its Q3 results to gain from a high rate of customer conversions toward it compared with its primary competitor.
Rockwell Medical on Expansion Spree: Should You Buy the Stock Now?
by Urmimala Biswas
This year can be regarded as a momentous period for RMTI's business because this is the first time in its history that it has achieved steady revenue growth.
Rockwell Medical Stock Surges 108.5% YTD: Should You Snap it Up Now?
by Urmimala Biswas
RMTI continues to outperform its peers, banking on its focus on optimizing business to drive sustainable profitability and meaningful cash flow generation.
Iridex (IRIX) Reports Q2 Loss, Misses Revenue Estimates
by Zacks Equity Research
Iridex (IRIX) delivered earnings and revenue surprises of -33.33% and 1.32%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Iridex (IRIX) Reports Q1 Loss, Misses Revenue Estimates
by Zacks Equity Research
Iridex (IRIX) delivered earnings and revenue surprises of -75% and 1.99%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
Lumentum (LITE) Q3 Earnings Beat Estimates
by Zacks Equity Research
Lumentum (LITE) delivered earnings and revenue surprises of 11.54% and 0.01%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
Iridex (IRIX) Reports Q4 Loss, Lags Revenue Estimates
by Zacks Equity Research
IRIDEX (IRIX) delivered earnings and revenue surprises of -260% and 16.39%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
Zacks Industry Outlook Highlights MicroVision, Cutera and IRIDEX
by Zacks Equity Research
MicroVision, Cutera and IRIDEX have been highlighted in this Industry Outlook article.
3 Laser Systems Stocks to Watch in a Challenging Industry
by Aniruddha Ganguly
The Zacks Laser Systems and Components industry participants like MicroVision (MVIS), Cutera (CUTR) and IRIDEX Corporation (IRIX) gain from solid demand for emerging applications like autonomous driving, IoT, 5G and healthcare amid challenging macroeconomic conditions.